Results of the EVOLVE trial reported at TCT 2011

A clinical trial has established the non-inferiority of a drug-eluting stent with a bioabsorbable polymer compared to a drug-eluting stent with a durable polymer. Results of the EVOLVE clinical trial were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

Durable polymer coatings on drug-eluting stents have been associated with and impaired healing. Bioabsorbable polymer-coated drug-delivery systems may reduce the risk of late events, including stent , and the need for prolonged dual antiplatelet therapy.

The EVOLVE trial is a prospective, multi-center, randomized, single blind, first in-human non-inferiority trial. Subjects were randomized 1:1:1 to either of two formulations of a stent (full or one-half dose) with the bioabsorbable polymer and a standard drug-eluting stent.

The primary clinical endpoint was the 30-day rate of target lesion failure, defined as related to the target vessel (TV), related to the TV, or target lesion revascularization. The primary angiographic endpoint was 6-month in-stent late loss.

A total of 291 subjects were enrolled in the EVOLVE trial between July 29, 2010 and January 20, 2011 at 29 sites in Europe, Australia, and New Zealand. The mean subject age was 63 years, 73.1% were male, and 19.3% had medically treated diabetes.

In the bioabsorbable stent group with the full dose (n= 94), late loss at six months was .10 mm and 30-day target lesion failure was 1.1%. In the bioabsorbable stent group with ½ dose (n=99), late loss at six months was 0.13 mm and 30-day target lesion failure was 3.1%.

These results compare to the use of a traditional drug-eluting stent (n=98), in which late loss at 6 months was .15 mm and 30-day target lesion failure was 0%.

"Clinical events were low and comparable with no stent thromboses in any group," said lead investigator, Ian T. Meredith, MBBS, PhD. Dr. Meredith is Professor and Director of Monash HEART and Executive Director of Monash Cardiovascular Research Centre at Monash Medical Centre and Monash University in Melbourne, Australia.

"These results support the safety and efficacy of the novel abluminal bioabsorbable polymer everolimus-eluting stent for the treatment of patients with de novo coronary artery disease. Additional research is needed to evaluate clinical event rates and the potential for dual reduction with this novel stent. " said Prof. Meredith.

Provided by Cardiovascular Research Foundation

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Results of the DESERT registry reported at TCT 2011

Nov 09, 2011

The risk of late stent thrombosis (ST) in the first generation of drug-eluting stents continues for up to seven years after implantation, and certain types of patients, including smokers and those who are younger, are at ...

Recommended for you

Barriers preventing post-stroke care

55 minutes ago

For stroke victims, rehabilitation is crucial to their recovery. But a Flinders University study conducted in Singapore found that rehabilitation rates following discharge from hospital are poor because of gaps in the continuum ...

Home-based rehabilitation for CVD patients

1 hour ago

Patients who are found to suffer from cardiovascular diseases often have long years of treatment ahead of them and are urged to drastically change their lifestyle. But what is probably the most difficult ...

New remote patient monitoring devices available

4 hours ago

(HealthDay)—Several new remote patient monitoring devices with useful applications are available or under development, according to an article published July 8 in Medical Economics.

Monitoring pulse after stroke may prevent a second stroke

15 hours ago

New research suggests that regularly monitoring your pulse after a stroke or the pulse of a loved one who has experienced a stroke may be a simple and effective first step in detecting irregular heartbeat, a major cause of ...

User comments